Introduction c-Myc is an oncoprotein that is significantly overexpressed in most human cancers, and experimental overexpression of c-Myc induces tumour formation in many organs (Pelengaris et al., 2002) . However, the cellular pathways that are regulated by Myc to drive tumour formation remain an intriguing mystery. Microarray technology has now revealed that c-Myc is an expansive transcription factor: upregulation of c-Myc in a gamut of cell types consistently modulates expression of 5-15% genes (Cowling and Cole, 2006; Dang et al., 2006) . What has also become apparent from these studies is that c-Myc acts in a cell context-dependent manner and regulates different genes and pathways in different cell types (Dang et al., 2006) . This raises the possibility that c-Myc may contribute to tumour formation in different cell types by regulating different pathways. Indeed, it is clear that different cancers have distinct pathways which are mutated to achieve tumour formation and metastasis.
Over 80% of human cancer is epithelial in origin, but little is known about which pathways c-Myc regulates to induce epithelial cell transformation. Some c-Mycregulated genes have a role in cellular processes that are common to all cell types, for example, c-Myc upregulates certain cycline-dependent kinases (CDKs) and cyclins, and represses CDK inhibitors (Dang et al., 2006) . However, there are likely to be signalling pathways peculiar to epithelial cells that must be modulated to induce tumour formation. c-Myc may induce tumour formation by regulating some of these epithelial cellspecific pathways.
Epithelial cells are restricted in their ability to grow outside their normal environment. For an epithelial cell tumour to metastasize, the cellular signalling pathways must undergo dramatic changes that permit cell survival and proliferation at non-physiological locations. A hallmark of this change is the 'epithelial to mesenchymal transition' (EMT) (Thiery, 2002) . During EMT, cells lose epithelial cell characteristics, gain fibroblastoid morphology and undergo a collection of changes thought to be necessary for cells to escape, survive and proliferate away from the epithelial cell environment.
Repression of E-cadherin expression and mutations in the E-cadherin gene are prevalent in many epithelial cancers (Christofori and Semb, 1999) . Experimentally, E-cadherin repression has been shown to be a ratelimiting step in the progression from adenoma to carcinoma (Perl et al., 1998) . In addition, E-cadherin has been shown to function as a tumour suppressor independent of its function in an adhesion complex by sequestering b-catenin away from the nucleus (Gottardi et al., 2001; Stockinger et al., 2001 ). Here we report that E-cadherin expression is repressed upon c-Myc overexpression and that this loss of E-cadherin expression is necessary for full c-Myc-dependent transformation of mammary epithelial cells.
Results and discussion
The role of c-Myc in tumours of epithelial origin is poorly characterized. To investigate the pathways activated by c-Myc in epithelial cells, we overexpressed c-Myc in TERT-immortalized human mammary epithelial cells (IMEC) (DiRenzo et al., 2002) . The level of c-Myc expression was similar to that in human breast cancer cell lines, which have substantially higher levels of c-Myc than normal epithelia (Cowling et al., manuscript submitted) . Immediately following transduction with exogenous c-Myc, the mammary epithelial cells underwent a dramatic change in cell morphology ( Figure 1a ). IMECs have a regular cubiodal morphology typical of epithelial cells and are well contact inhibited. Elevated expression of c-Myc-induced a Figure 1 c-Myc represses E-cadherin expression by a post-transcriptional mechanism. (a) Phase-contrast micrographs of human immortalized mammary epithelial cells (IMEC) expressing c-Myc or vector control. IMECs were infected with retroviruses containing LXSH (vector) or LXSH-c-Myc, and pools were selected using hygromycin. Exogenous expression of c-Myc in IMECs was detected by IP-western performed on equivalent amounts of cell extracts (IP-FLAG monoclonal (Sigma A2220, St Louis, MO, USA)), WB c-Myc polyclonal antibodies (Santa Cruz N262, Santa Cruz, CA, USA). (b) RIPA extracts were prepared from IMEC/vector and IMEC/ c-Myc, normalized for protein content and Western blots were performed using anti-E-cadherin antibodies (Cell Signaling Technology #4065, Danvers, MA, USA) and anti-tubulin antibodies (Santa Cruz #H235, Santa Cruz, CA, USA). Cell extracts were also prepared in 0.1% NP-40. Cell extracts were normalized for protein content, and Western blots were performed on these extracts and whole-cell extracts using anti-fibronectin and anti-vimentin antibodies (both from Sigma F3648 and V6630). (c) RNA was extracted from logphase IMEC lines and RT-PCR was performed using primers specific for E-cadherin (sequences available on request). Input RNA was titrated to ensure RT-PCR was performed in the linear range. Primers were 32P labelled to allow quantitation of RT-PCR products resolved on an acrylamide gel (Molecular Dynamics, ImageQuant). Error bars indicate s.d. of independent experiments. (d) RT-PCR was performed as above, using primers specific for E-cadherin and GAPDH. As a positive control for E-cadherin, RT-PCR was also performed on IMECs expressing an exogenous E-cadherin cDNA. Expression of E-cadherin relative to GAPDH in IMEC/vector and IMEC/c-Myc was calculated for independent experiments. Error bars indicate s.d.
E-cadherin repression in c-Myc-induced EMT VH Cowling and MD Cole fibroblastoid morphology. The cells became darker and more refractile, and they were less contact inhibited, permitting growth to a higher density. This change in morphology was reproduced on several independent infections. This change in morphology suggested that EMT may have occurred (Thiery, 2002) . To further characterize this c-Myc-induced morphological change, we analysed expression of three EMT markers: E-cadherin, fibronectin and vimentin.
E-cadherin is a transmembrane protein that mediates the major cell-cell adhesions in epithelial cells, a function that has been linked to its role as a tumour suppressor (Beavon, 2000) . Loss of E-cadherin expression is a marker of EMT (Thiery, 2003) . Whole-cell extracts were made from IMECs expressing c-Myc or vector control, and a Western blot was performed using an anti-E-cadherin antibody (Figure 1b ). E-cadherin was found to be substantially repressed in response to c-Myc, which is consistent with EMT having occurred. Detection of g-tubulin was used as a loading control for the cell extracts. Fibronectin is a glycoprotein whose upregulation is a marker of EMT (Thiery, 2003) . Fibronectin upregulation has also been correlated with metastasis (Bittner et al., 2000; Clark et al., 2000) . Western blots performed on the IMEC whole-cell extracts showed that the fibronectin expression level was unaltered in response to c-Myc expression (Figure 1b) . However, we found that the solubility of fibronectin did change in response to c-Myc. In control IMECs, fibronectin was largely insoluble in 0.1% NP-40. Overexpression of c-Myc significantly increased the solubility of fibronectin in 0.1% NP-40 (Figure 1b) . Vimentin is an intermediate filament whose upregulation is also a marker of EMT. Increased vimentin expression has been correlated with the reduced survival of breast cancer patients (Niveditha and Bajaj, 2003) . Overexpression of c-Myc also increased the solubility of vimentin, with the total cellular expression remaining unchanged (Figure 1b) . In summary, c-Myc expression induces two well-established hallmarks of EMT, that is, fibroblastoid morphology and E-cadherin repression. c-Myc expression does not upregulate the fibroblastoid markers, vimentin and fibronectin rather it alters their solubility. To our knowledge, this is the first description of a change in solubility of EMT markers occurring coincident with more traditional EMT markers.
In previously described examples of EMT induction, repression of E-cadherin was found to be transcriptional (Batlle et al., 2000; Cano et al., 2000) . In order to determine whether c-Myc-dependent repression of E-cadherin expression is transcriptional, we analysed E-cadherin mRNA levels in IMECs expressing c-Myc or vector control. RNA was extracted from the IMEC lines, and reverse transcriptase-PCR (RT-PCR) was performed using primers specific for E-cadherin (Figure 1c ). Input RNA was titrated for both cell lines to ensure that reactions were being carried out in the linear range and were therefore quantitative, that is, when input RNA was halved, E-cadherin RT-PCR signal halved. Use of 32 P-labelled primers allowed quantitation of PCR products resolved on acrylamide gels. We found that E-cadherin mRNA was not repressed in response to c-Myc, and the expression level was comparable between IMEC/vector and IMEC/ c-Myc (Figure 1c) . As an independent confirmation that E-cadherin was not being repressed by c-Myc expression, we calculated E-cadherin mRNA levels relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). As a positive control for E-cadherin mRNA, we carried out RT-PCR on IMECs overexpressing E-cadherin, which gave a robust signal (Figure 1d) . Quantitation of independent experiments confirmed that E-cadherin mRNA expression was not c-Myc-regulated relative to GAPDH (Figure 1d ) or relative to total RNA (Figure 1c) . We also used additional sets of primers specific for E-cadherin to confirm independently that E-cadherin is not repressed by c-Myc (not shown).
Previous experiments have shown that expression of E-cadherin can inhibit both cell proliferation and transformation (Gottardi et al., 2001; Stockinger et al., 2001) . With this in mind, we wanted to test if repression of E-cadherin is required for c-Myc-induced proliferation and transformation. To this end, we transduced an E-cadherin cDNA expression vector into the parental IMEC cell line and into IMEC/c-Myc cells in which E-cadherin is repressed. These lines were compared to empty vector controls. Following selection, we verified that infection with the E-cadherin vector resulted in upregulation of E-cadherin expression (Figure 2a) . We measured the proliferation rate of these four cell lines by counting cells on sequential days (Figure 2b ). The
Figure 2 E-cadherin repression is not required for c-Myc-induced cell proliferation. (a) IMECs expressing LXSH or LXSH-c-Myc were infected with retroviruses containing BMN-IRES-neo (vector) or BMN-E-cadherin-IRES-neo, and pools were selected using G418. Whole-cell extracts were prepared and normalized, and Western blots were performed using anti-E-cadherin or antitubulin antibodies. (b) Growth curves for log-phase IMEC cells infected with the indicated constructs.
E-cadherin repression in c-Myc-induced EMT
VH Cowling and MD Cole doubling time of IMEC cells was about 23 h, whereas c-Myc expression alone decreased the doubling time to 16 h. Overexpression of E-cadherin did not repress or enhance the cell proliferation rate in either background. Thus, we conclude that repression of E-cadherin is not necessary for the enhanced rate of cell proliferation induced by c-Myc overexpression. We investigated the role of E-cadherin repression in c-Myc-induced cell transformation. We assayed the IMEC lines for growth in soft agar, which is a measure of anchorage-independent growth and a hallmark of many tumour cells. The parental IMECs are a normal epithelial cell line and, as expected, the control cell line could not grow in an anchorage-independent manner when plated in soft agar (Figure 3a and b) . Expression of c-Myc in these cells, however, induced about 70% of the plated cells to grow into colonies in soft agar. Hence, the c-Myc/IMEC cell line can be defined as partially transformed. To determine if repression of E-cadherin was necessary for c-Myc-induced cell transformation, we plated the c-Myc/E-cadherin/IMECs in soft agar. We found that only about 35% of the plated cells grew into robust colonies, approximately twofold less than c-Myc/IMECs (Figure 3b ). Therefore repression of E-cadherin is necessary for c-Myc to induce cell transformation of mammary epithelial cells.
Many breast cancer cell lines are deficient for E-cadherin expression (Graff et al., 1995) . Therefore, we wanted to extend our findings with IMECs to determine if E-cadherin repression contributes to the transformed phenotype of breast cancer cell lines. We expressed E-cadherin in MDA-231 cells, a breast cancer cell line that is null for E-cadherin expression. Exogenous E-cadherin expression was confirmed by Western blot (Figure 3c ).
We performed a soft agar assay on vector/MDA-231 and E-cadherin/MDA-231 and found that E-cadherin expression repressed anchorage-independent growth to approximately the same extent as in E-cadherin/c-Myc/ IMECs (Figure 3c ).
Many epithelial tumours, including breast cancer tumours, are not fatal in themselves, but death results from metastases to other organs. Mammary epithelial cells, like all epithelial cells, are restricted in their growth by extracellular signals provided by other cells and the extracellular matrix. For epithelial cells to become metastatic, they must change their morphology and acquire the ability to escape the control of these survival signals, that is, undergo an EMT (Thiery, 2002 (Thiery, , 2003 . Here we present data that Myc-induced mammary epithelial cells exhibit some hallmarks of EMT. Rapidly following c-Myc overexpression, IMEC cells exhibit a fibroblastoid morphology, become less adherent and strongly repress E-cadherin protein levels. These observations suggest that c-Myc may rapidly induce a phenotype that favours metastasis in this cell lineage. Additionally, the fact that ectopic E-cadherin can repress soft agar colony formation indicates that E-cadherin repression may also be rate-limiting for primary tumour formation under some circumstances. Besides E-cadherin, Myc can repress the expression of many other proteins involved in cell adhesion and the cytoskeleton (Shiio et al., 2002) . The combined effects of these proteomic changes may account for an EMT-like phenotype in epithelial cells. How c-Myc specifically induces the hallmarks of EMT in mammary epithelial cells is unresolved, and we are currently investigating other Myc-regulated genes that may mediate this process. (c) MDA-231 cells were infected with retroviruses containing E-cadherin or vector control, and pools were selected using G418. RIPA extracts were prepared, normalized for protein content and Western blots were performed using anti-E-cadherin and anti-tubulin antibodies. (d) MDA-231cell lines were plated in soft agar as in (a) and colonies were counted as in (b).
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